Manufacturers report negative results for avapritinib vs regorafenib in advanced gastrointestinal stromal tumour

In the phase 3 VOYAGER Trial, avapritinib (tyrosine kinase inhibitor designed to selectively inhibit PDGFRa and KIT) did not improve progression free survival vs regorafenib in patients with third- or fourth-line gastrointestinal stromal tumour treatment.


Biospace Inc.